Targeting both macrophages and microglia through LOX inhibition and modulation of the CLOCK-OLFML3 axis, in combination with anti-PD-1 therapy, has demonstrated significant antitumor effects, highlighting a promising therapeutic strategy for GBM.174 This mechanism underscores the role of PTEN in modulating both cellular and microenvironmental factors in GBM progression. The gene discussed is LOX; the disease is glioblastoma.